News

25. September 2023

Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology

Read Article

7. September 2023

DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers

Read Article

17. April 2023

Glycotope Presents Glyco-Engineered Cell Lines at the 2023 American Association for Cancer Research (AACR) Meeting

Read Article

17. January 2023

Glycotope Presents Glyco-Engineered Cell Lines at GlycoBioTec 2023 – 3rd International GlycoBioTec Symposium

Read Article

13. December 2022

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer

Read Article

8. November 2022

Glycotope Presents GlycoTarget Platform and New Data on Platform-Derived anti-LYPD3 Antibody at 2022 Society for Immunotherapy of Cancer (SITC) Meeting

Read Article

12. July 2022

LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate

Read Article

8. April 2022

Glycotope Presents New Data on Antibodies and Fusion-Proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) Meeting

Read Article

24. March 2022

Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform

Read Article

1. February 2022

Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH

Read Article